

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended	
	March 31, 2013	
	International	Total
	Net Sales	Net Sales
Net sales, as reported	\$ 52,550	\$ 120,355
Currency impact as compared to prior period	2,138	2,138
Net sales, excluding the impact of foreign currency	\$ 54,688	\$ 122,493

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended	
	March 31, 2013	March 31, 2012⁽¹⁾
Operating Income		
Operating income, as reported	\$ 8,234	\$ 9,661
<i>Reconciling items impacting Gross Profit:</i>		
Cost of sales - restructuring	—	435
Inventory step-up amortization	108	48
Total	108	483
<i>Reconciling items impacting Selling, General and Administrative expense:</i>		
U.S. governmental inquiries/DPA related	1,096	2,868
Distributor conversions	357	—
Due diligence, transaction and transition costs ⁽²⁾	7,498	—
Product liability insurance recovery	(19,376)	—
Total	(10,425)	2,868
<i>Reconciling items impacting Amortization of Intangible Assets:</i>		
Amortization of distributor non-competes	1,292	—
<i>Other Reconciling Items:</i>		
Restructuring charges	—	443
Operating (loss) income, as adjusted	\$ (791)	\$ 13,455
Operating (loss) income, as adjusted, as a percentage of net sales	(0.7)%	10.6%

(1) Beginning in 2013, we do not adjust our reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

(2) Includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended	
	March 31, 2013	March 31, 2012 ⁽¹⁾
Net Income		
Income before taxes, as reported	\$ 10,040	\$ 7,693
<i>Pre-tax impact of reconciling items:</i>		
U.S. governmental inquiries/DPA related	1,096	2,868
Restructuring charges	—	878
Inventory step-up amortization	108	48
Distributor conversion and non-competes	1,649	—
Non-cash interest expense on 2017 Convertible Notes	2,117	—
Derivatives mark-to-market adjustment	2,000	—
Due diligence, transaction and transition costs ⁽²⁾	7,498	—
Product liability insurance recovery	(19,376)	—
Gain on previously held investment in BioMimetic	(7,798)	—
(Loss) income before taxes, as adjusted	(2,666)	11,487
Provision for income taxes, as reported	\$ 1,605	\$ 3,132
U.S. governmental inquiries/DPA related	423	1,465
Restructuring charges	—	343
Inventory step-up amortization	42	19
Distributor conversion and non-competes	637	—
Non-cash interest expense on 2017 Convertible Notes	818	—
Derivatives mark-to-market adjustment	778	—
Due diligence, transaction and transition costs	1,439	—
Product liability insurance recovery	(7,486)	—
Gain on previously held investment in BioMimetic	—	—
(Benefit) provision for income taxes, as adjusted	\$ (1,744)	\$ 4,959
Effective tax rate, as adjusted	65.4%	43.2%
Net (loss) income, as adjusted	\$ (922)	\$ 6,528

(1) Beginning in 2013, we do not adjust our reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

(2) Includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended March 31, 2013		Three Months Ended March 31, 2012 ⁽¹⁾	
	As Reported	As Adjusted	As Reported	As Adjusted
Basic net income (loss)	\$ 8,435	\$ (922)	\$ 4,561	\$ 6,528
Interest expense on convertible notes	18	N/A	N/A	137
Diluted net income (loss)	\$ 8,453	\$ (922)	\$ 4,561	\$ 6,665
Basic shares	41,438	41,438	38,492	38,492
Dilutive effect of stock options and restricted shares	586	N/A	334	334
Dilutive effect of convertible notes	115	N/A	N/A	891
Diluted shares	42,139	41,438	38,826	39,717
Net income (loss) per share, diluted	\$ 0.20	\$ (0.02)	\$ 0.12	\$ 0.17

(1) Beginning in 2013, we do not adjust our reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended	
	March 31, 2013	March 31, 2012 ⁽¹⁾
Net Income per Diluted Share		
Net income, as reported, per diluted share	\$ 0.20	\$ 0.12
Interest expense on convertible notes	0.00	0.00
Effect of convertible notes on diluted shares	(0.00)	(0.00)
U.S. governmental inquiries/DPA related	0.02	0.04
Restructuring charges	—	0.01
Inventory step-up amortization	0.00	0.00
Distributor conversion and non-competes	0.02	—
Non-cash interest expense on 2017 Convertible Notes	0.03	—
Derivatives mark-to-market adjustment	0.03	—
Due diligence, transaction and transition costs	0.15	—
Product liability insurance recovery	(0.29)	—
Gain on previously held investment in BioMimetic	(0.19)	—
Net (loss) income, as adjusted, per diluted share ⁽²⁾	\$ (0.02)	\$ 0.17

(1) Beginning in 2013, we do not adjust our reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

(2) Reconciling items may not add to total net income, as adjusted, per diluted share due to rounding differences.

Wright Medical Group, Inc.
Reconciliation of Free Cash Flow
(dollars in thousands--unaudited)

	Three Months Ended	
	March 31, 2013	March 31, 2012
Net cash (used in) provided by operating activities	\$ (5,168)	\$ 19,080
Capital expenditures	(3,740)	(4,531)
Free cash flow	<u>\$ (8,908)</u>	<u>\$ 14,549</u>